Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy: Novel Compounds II

Session Type: ACR Abstract Submissions
Wednesday, November 9, 2011: 11:00 AM-12:30 PM
W196b (McCormick Place West)
SessionSelect
Moderators: Stanley B. Cohen, MD, Metroplex Clinical Research Centre and Veena K. Ranganath, MD, University of California, Los Angeles
Papers:
11:00 AM
Tofacitinib (CP-690,550) in Combination with Traditional Disease-Modifying Anti-Rheumatic Drugs: Phase 3 Study Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis and An Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs
V. Strand1, J. M. Kremer2, Z. G. Li3, S. Hall4, Roy M. Fleischmann5, M. C. Genovese6, E. Martin-Mola7, J. Isaacs8, D. Gruben9, G. Wallenstein9, S. Krishnaswami9, S. H. Zwillich9, T. Koncz10, R. Riese9, J. D. Bradley9 and the ORAL Sync investigators11, 1Stanford University, Palo Alto, CA, 2Albany Medical College and The Center for Rheumatology, Albany, NY, 3Peking University People's Hospital, Peking, China, 4Melbourne Rheumatology, Melbourne, Australia, 5MCRC, University of Texas, Dallas, TX, 6Stanford University Medical Center, Palo Alto, CA, 7Hospital Universitario La Paz, Madrid, Spain, 8University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom, 9Pfizer Inc., Groton, CT, 10Pfizer Inc., New York, NY, 11Groton
11:15 AM
Double-Blind Study of Tocilizumab Plus Methotrexate Vs Tocilizumab Plus Placebo in Patients with Active Rheumatoid Arthritis Despite Prior Methotrexate: Progression of Structural Damage, Quality of Life, and Physical Function At 24 Weeks
Maxime Dougados, Paris-Descartes University, Cochin Hospital, Paris, France, Karsten Kissel, F. Hoffmann-La Roche Ltd, Basel, Switzerland, Howard Amital, Sheba Medical Center, Tel-hashomer, Israel, Philip G. Conaghan, NIHR-Leeds Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, Emilio Martin-Mola, Hospital Universitario La Paz, Madrid, Spain, Evgeny L. Nasonov, Institute of Rheumatology, Moscow, Russia, Georg Schett, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, Orrin M. Troum, USC Keck School of Medicine, Santa Monica, CA, Tiina Veldi, East-Tallinn Central Hospital, Tallinn, Estonia, Corrado Bernasconi, Roche, Basel, Switzerland and T.W.J. Huizinga, Leiden University Medical Center, Leiden, Netherlands
11:30 AM
Postmarketing Surveillance of Tocilizumab for Rheumatoid Arthritis In Japan – Full Analysis Report of 7,901 Patients
Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, Masayoshi Harigai, Tokyo Medical and Dental Univ, Tokyo, Japan, Shigeko Inokuma, Japanese Red Cross Medical Center, Tokyo, Japan, Naoki Ishiguro, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, Junnosuke Ryu, Nihon University School of Medicine, Tokyo, Japan, Syuji Takei, Kagoshima University, Kagoshima City, Japan, Tsutomu Takeuchi, Keio University School of Medicine, Tokyo, Japan, Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan, Youko Sano, Chugai Pharmaceutical Co. Ltd., Tokyo, Japan and Takao Koike, Sapporo Medical Center NTT EC, Sapporo, Japan
11:45 AM
A Multiple Ascending Dose / Proof of Concept Study of ATN-103 (ozoralizumab) in Rheumatoid Arthritis Subjects on a Background of Methotrexate
Roy Fleischmann1, Savithree Nayiager2, Ingrid Louw3, Bernadette Rojkovich4, Caifeng Fu5, Chandrasekhar Udata6, Parvin Fardipour7, Bonnie Marshall7, Michelle Hinz7, Amarnath Sharma7, Kathy Shields7 and Gail Comer7, 1Metroplex Clinical Research Center, Dallas, TX, 2St. Augustine Hospital, Berea, KwaZulu-Natal, South Africa, 3Panorama Medical Centre, Panorama, Western Cape, South Africa, 4Polyclinic of the Hospitaller Brothers of St John of God, Budapest, Hungary, 5Pfizer, Cambridge, MA, 6Pfizer, La Jolla, CA, 7Pfizer, Collegeville, PA
12:00 PM
Results From a 2-Part, Proof-of-Concept, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Sirukumab, a Human Anti-Interleukin-6 Monoclonal Antibody, in Active Rheumatoid Arthritis Patients Despite Methotrexate Therapy
Benjamin Hsu, Centocor R&D, a division of J&J Pharmaceutical R& D, LLC/Univ. of Pennsylvania, Malvern/Philadelphia, PA, Shihong Sheng, Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, Josef Smolen, Medical University of Vienna and Hietzing Hospital, Vienna, Austria and Michael E. Weinblatt, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
12:15 PM
Results From a Multicenter, International, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Sirukumab, a Human Anti-IL-6 Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy
Benjamin Hsu, Centocor R&D, a division of J&J Pharmaceutical R& D, LLC/Univ. of Pennsylvania, Malvern/Philadelphia, PA, Shihong Sheng, Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, Michael E. Weinblatt, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA and Josef Smolen, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
See more of: ACR Abstract Submissions

To see other sessions for this day, use the date buttons to the left.